{"id":8318,"date":"2024-04-15T01:52:34","date_gmt":"2024-04-15T01:52:34","guid":{"rendered":"https:\/\/economicherald.net\/?p=8318"},"modified":"2024-04-15T01:52:34","modified_gmt":"2024-04-15T01:52:34","slug":"asx-health-stocks-atomo-sells-more-hiv-self-tests-actinogen-begins-phase-2b-trial-on-alzheimers","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=8318","title":{"rendered":"ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s"},"content":{"rendered":"<p>Atomo announces more purchase orders for HIV Self-Tests<br \/>\nActinogen says first patient was treated in Alzheimer\u2019s disease study<br \/>\nImugene has opened\u00a0enrolment for expansion study in solid tumours<\/p>\n<p>\u00a0<\/p>\n<h2>Atomo sells more HIV self-test kits<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/atomo-diagnostics-at1\/\">Atomo Diagnostics (ASX:AT1)<\/a><\/strong> rose 10% this morning after announcing purchase orders from <strong>Viatris Healthcare<\/strong> for approximately $570,000 worth of <strong>HIV Self-Tests.<\/strong><\/p>\n<p>These products are manufactured by Atomo under the <em>Mylan<\/em> brand for supply to several Low- and Middle-Income Countries (LMICs).<\/p>\n<p>The orders are for manufacture in the coming months, and Atomo considers the revenue from these orders to be material.<\/p>\n<p>\u201cWe are delighted to see Viatris, our global health partner, continues to secure orders across LMIC markets,\u201d said Atomo\u2019s founder and CEO, John Kelly.<\/p>\n<p>\u201cRecent growth in our global health markets mirrors anticipated growth here in Australia from emerging public health channels, and we are encouraged by the ongoing transition of diagnostic testing demand from healthcare facilities to self-test channels.\u201d<\/p>\n<p>Atomo offers the world\u2019s first blood-based rapid diagnostic test (RDT) for HIV screening. Unlike clinical testing, the Atomo HIV Self Test provides results in just 15 minutes.<\/p>\n<p>The Atomo HIV Self Test has been proven to be highly accurate, with a specificity and sensitivity level of 99.6%. The tests also allow users to comfortably carry them out in a private and discreet setting.<\/p>\n<p>Today\u2019s $570k purchase order from Viatris follows the $970k purchase order, also from Viatris, back in March.<\/p>\n<p>\u00a0<\/p>\n<h2>Actinogen commences Phase 2b trial on Alzheimer\u2019s<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/actinogen-medical-acw\/\">Actinogen Medical (ASX:ACW)<\/a><\/strong> also rose 10% this morning after announcing that the first patient was randomised and treated on Friday 12 April, in the <strong>XanaMIA Phase 2b clinical trial<\/strong> in patients with Alzheimer\u2019s disease (AD).<\/p>\n<p>The trial of 220 participants, with elevated levels of the blood <strong>biomarker pTau,<\/strong> measures the effects of a <strong>Xanamem 10mg<\/strong> daily dose versus placebo over a 36-week treatment period.<\/p>\n<p>The trial has commenced at 13 Australian sites and will subsequently expand to the US.<\/p>\n<p>The trial was designed to confirm that Xanamem is a safe and effective new treatment for Alzheimer\u2019s disease.\u00a0The primary endpoint is a cognitive test battery comprising seven different digital assessments.<\/p>\n<p><strong>Dr Steven Gourlay<\/strong>, Actinogen\u2019s CEO and MD, said Xanamem represents a major opportunity for patients and the company.<\/p>\n<p>\u201cThe clear priority for the next 18 months is to deliver high quality results from our on-going Phase 2 clinical trials in depression and Alzheimer\u2019s disease, the first of which will report results in Q3 this year.\u201d<\/p>\n<p>\u00a0<\/p>\n<h2>Imugene opens expansion study<\/h2>\n<p>Meanwhile, <strong><a href=\"https:\/\/stockhead.com.au\/company\/imugene-imu\/\">Imugene (ASX:IMU)<\/a><\/strong> announced that enrolment has opened for an\u00a0<strong>expansion study<\/strong> in the <strong>MAST (Metastatic Advanced Solid Tumours) Phase 1 trial<\/strong> treating 10 bile tract cancer (cholangiocarcinoma) patients.<\/p>\n<p>This follows the completion of the fifth, high dose cohort in the intratumoural (IT) arm of the monotherapy dose escalation study evaluating its cancer-killing<br \/>\n virus,\u00a0<strong>CF33-hNIS (VAXINIA).<\/strong><\/p>\n<p>That cohort has now been cleared with no safety signals seen to date. The cohort included patients with thymic carcinoma, triple negative breast cancer and <strong>cholangiocarcinoma<\/strong>.<\/p>\n<p>Cholangiocarcinoma is a rare disease in which malignant cancer cells form in the bile ducts. It is difficult to treat and generally responds poorly to immunotherapy drugs.<\/p>\n<p>In November 2023, the FDA granted the VAXINIA MAST clinical program Fast Track Designation for the treatment of bile duct cancer (cholangiocarcinoma), which allows Imugene closer cooperation with the FDA to expedite the program and potential approval process.<\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-atomo-sells-more-hiv-self-tests-actinogen-begins-phase-2b-trial-on-alzheimers\/\">ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Atomo announces more purchase orders for HIV Self-Tests Actinogen says first patient was treated in Alzheimer\u2019s disease study Imugene has opened\u00a0enrolment for expansion study in <a href=\"https:\/\/economicherald.net\/?p=8318\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":8319,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-8318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=8318\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Atomo announces more purchase orders for HIV Self-Tests Actinogen says first patient was treated in Alzheimer\u2019s disease study Imugene has opened\u00a0enrolment for expansion study in [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=8318\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-15T01:52:34+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8318#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8318\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s\",\"datePublished\":\"2024-04-15T01:52:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8318\"},\"wordCount\":598,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8318#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Atomo-announces-more-purchase-orders-for-HIV-Self-Tests.-Picture-Getty-LS4Zak.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8318\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=8318\",\"name\":\"ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8318#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8318#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Atomo-announces-more-purchase-orders-for-HIV-Self-Tests.-Picture-Getty-LS4Zak.jpeg\",\"datePublished\":\"2024-04-15T01:52:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8318#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=8318\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8318#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Atomo-announces-more-purchase-orders-for-HIV-Self-Tests.-Picture-Getty-LS4Zak.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Atomo-announces-more-purchase-orders-for-HIV-Self-Tests.-Picture-Getty-LS4Zak.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8318#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=8318","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s - Economic Herald","og_description":"Atomo announces more purchase orders for HIV Self-Tests Actinogen says first patient was treated in Alzheimer\u2019s disease study Imugene has opened\u00a0enrolment for expansion study in [more...]","og_url":"https:\/\/economicherald.net\/?p=8318","og_site_name":"Economic Herald","article_published_time":"2024-04-15T01:52:34+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=8318#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=8318"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s","datePublished":"2024-04-15T01:52:34+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=8318"},"wordCount":598,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=8318#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Atomo-announces-more-purchase-orders-for-HIV-Self-Tests.-Picture-Getty-LS4Zak.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=8318","url":"https:\/\/economicherald.net\/?p=8318","name":"ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=8318#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=8318#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Atomo-announces-more-purchase-orders-for-HIV-Self-Tests.-Picture-Getty-LS4Zak.jpeg","datePublished":"2024-04-15T01:52:34+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=8318#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=8318"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=8318#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Atomo-announces-more-purchase-orders-for-HIV-Self-Tests.-Picture-Getty-LS4Zak.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/Atomo-announces-more-purchase-orders-for-HIV-Self-Tests.-Picture-Getty-LS4Zak.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=8318#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer\u2019s"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/8318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8318"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/8318\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/8319"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}